Canopy Growth (FRA:11L) Loans Receivable: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:11L Canopy Growth Corp FRA:11L
36 GF Score
Price €0.91
GF Value €0.62
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Canopy Growth Loans Receivable?

Canopy Growth FRA:11L +5.06% 36 Loans Receivable is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:11L with a GF Score™ of 36/100 and a GF Value™ of €0.62 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Canopy Growth's Loans Receivable for the quarter that ended in Jun. 2026 was €0.0 Mil.

Canopy Growth Loans Receivable Historical Data

* Premium members only.

The historical data trend for Canopy Growth's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canopy Growth Loans Receivable Chart

Canopy Growth Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Canopy Growth Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:11L
36GF Score
Canopy Growth Corp FRA:11L
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canopy Growth Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.0 Mil mean?
Canopy Growth (FRA:11L) has a Loans Receivable of €0.0 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Canopy Growth and its competitors.
Is Canopy Growth's Loans Receivable too high?
Canopy Growth's current Loans Receivable is €0.0 Mil. Overall, Canopy Growth has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Loans Receivable compare to ZTS?
Canopy Growth's Loans Receivable of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Canopy Growth and its competitors. Canopy Growth's current Loans Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (FRA:11L) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.62, compared to a current price of €0.91 — trading 46% above its estimated fair value. The current Loans Receivable is €0.0 Mil. Canopy Growth's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Canopy Growth (FRA:11L), the current Loans Receivable is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canopy Growth (FRA:11L) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of €0.91 is trading 46% above its estimated GF Value™ of €0.62. GuruFocus considers Canopy Growth to be Significantly Overvalued.

Key valuation signals for FRA:11L:

  • Loans Receivable: €0.0 Mil
  • GF Value™: €0.62 vs. price of €0.91 (46% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the FRA:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canopy Growth Business Description

Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
36GF Score

Get the complete analysis for FRA:11L

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.91
Price
€0.62
GF Value